Before beginning any new therapy, it helps to understand the possible side effects. Most people tolerate NAD+ therapy well, but some side effects can occur. Here's what research and clinical experience suggest you might notice.

Common NAD Injection Side Effects

People who get NAD+ through subcutaneous or intramuscular injections usually report mild, local side effects. These can include a brief sting or mild soreness at the injection site. Some notice temporary redness or warmth, and a mild burning feeling can happen, especially with intramuscular shots.

These NAD injection side effects are similar to what you might experience with any subcutaneous or intramuscular injection and typically resolve within hours. Rotating injection sites and allowing the solution to reach room temperature before injecting can help minimize discomfort.

Side Effects During IV Infusions

IV NAD+ infusions, because they deliver larger doses directly into the bloodstream, can produce more noticeable NAD reactions during treatment. The most commonly reported sensations include chest tightness or pressure, nausea, abdominal cramping, lightheadedness, and anxiety or restlessness. These reactions are typically dose- and rate-dependent, meaning they're more likely at higher doses or faster drip rates.

Experienced providers manage these effects by starting with a slow drip rate and adjusting based on how you feel. If discomfort develops, slowing the infusion usually resolves the symptoms within minutes. Most patients tolerate subsequent sessions better as their body adjusts.

Are There Serious Risks?

Serious adverse events from NAD+ therapy are rare in the published literature and clinical practice. NAD+ is a naturally occurring molecule in your body, and supplementing it at therapeutic doses has not been associated with significant organ toxicity or dangerous systemic reactions in the studies conducted to date.

However, as with any therapy, individual responses vary. Patients with certain pre-existing conditions should discuss NAD+ therapy with their provider before starting. If you have any known sensitivity to the compound or its formulation ingredients, experience unusual or severe reactions during treatment, or have significant cardiovascular or metabolic conditions, your provider should evaluate whether NAD+ therapy is appropriate and, if so, which delivery method and dosing schedule is safest for you.

Managing Side Effects

For injection-related discomfort, the same strategies that help with any subcutaneous injection apply: let the solution warm to room temperature, inject slowly, and rotate your sites. For IV-related symptoms, communicate with your provider during the infusion. Adjusting the drip rate is usually all that's needed.

Some patients find that mild side effects diminish over the first few sessions as their body adjusts to the therapy. If side effects persist or worsen, your provider may adjust the dose, switch delivery methods, or modify your protocol.

The Bigger Picture

When weighing NAD+ side effects against potential benefits, most patients and clinicians find the risk-benefit profile to be favorable. The side effects are generally mild, temporary, and manageable, while the potential benefits—improved energy, better cognitive function, enhanced recovery—can be significant for the right candidate. The key is working with a provider who monitors your response and adjusts your treatment accordingly.

At HRT Wellness, we monitor every patient's experience closely and tailor protocols to minimize discomfort while maximizing results. Schedule a consultation to learn more about our NAD+ therapy program.

References

  1. Martens CR, et al. Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+. Nature Communications. 2018;9(1):1286.
  2. Yoshino J, Baur JA, Imai S. NAD+ intermediates: the biology and therapeutic potential of NMN and NR. Cell Metabolism. 2018;27(3):513–528.
  3. Braidy N, et al. Role of nicotinamide adenine dinucleotide and related precursors as therapeutic targets for age-related degenerative diseases. Antioxidants & Redox Signaling. 2019;30(2):187–208.